PL3280734T3 - Przeciwciała anty-flt-1 do leczenia dystrofii mięśniowej duchenne'a - Google Patents
Przeciwciała anty-flt-1 do leczenia dystrofii mięśniowej duchenne'aInfo
- Publication number
- PL3280734T3 PL3280734T3 PL16716795T PL16716795T PL3280734T3 PL 3280734 T3 PL3280734 T3 PL 3280734T3 PL 16716795 T PL16716795 T PL 16716795T PL 16716795 T PL16716795 T PL 16716795T PL 3280734 T3 PL3280734 T3 PL 3280734T3
- Authority
- PL
- Poland
- Prior art keywords
- flt
- antibodies
- muscular dystrophy
- duchenne muscular
- treating duchenne
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144251P | 2015-04-07 | 2015-04-07 | |
| US201662307645P | 2016-03-14 | 2016-03-14 | |
| EP16716795.6A EP3280734B1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies for treating duchenne muscular dystrophy |
| PCT/US2016/026352 WO2016164528A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies for treating duchenne muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3280734T3 true PL3280734T3 (pl) | 2022-07-04 |
Family
ID=55754471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16716795T PL3280734T3 (pl) | 2015-04-07 | 2016-04-07 | Przeciwciała anty-flt-1 do leczenia dystrofii mięśniowej duchenne'a |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10787515B2 (enExample) |
| EP (2) | EP4056593A1 (enExample) |
| JP (3) | JP6993880B2 (enExample) |
| CN (3) | CN120290577A (enExample) |
| AU (2) | AU2016246722B2 (enExample) |
| CA (1) | CA2981954A1 (enExample) |
| ES (1) | ES2910783T3 (enExample) |
| MA (1) | MA41899A (enExample) |
| MX (1) | MX2017012828A (enExample) |
| PL (1) | PL3280734T3 (enExample) |
| WO (1) | WO2016164528A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| JP2022513693A (ja) * | 2018-11-29 | 2022-02-09 | ハーバー・バイオメド・セラピューティクス・リミテッド | 抗ｐｄ－ｌ１抗体製剤 |
| PH12022550211A1 (en) * | 2019-08-02 | 2022-12-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anti-pd-1 antibody and medical use thereof |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| CN102397542B (zh) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| CN102307902B (zh) | 2008-12-10 | 2016-02-24 | 埃博灵克斯股份有限公司 | 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽 |
| WO2012109282A2 (en) | 2011-02-07 | 2012-08-16 | Agamin Pharmaceuticals, Llc | Methods and systems for treating or preventing pregnancy-related hypertensive disorders |
| CA2898998C (en) * | 2013-01-28 | 2023-02-14 | Regents Of The University Of Minnesota | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
| TW201517916A (zh) * | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
-
2016
- 2016-04-06 MA MA041899A patent/MA41899A/fr unknown
- 2016-04-07 CN CN202510178279.0A patent/CN120290577A/zh active Pending
- 2016-04-07 WO PCT/US2016/026352 patent/WO2016164528A1/en not_active Ceased
- 2016-04-07 CN CN202210037246.0A patent/CN114539408B/zh active Active
- 2016-04-07 US US15/564,976 patent/US10787515B2/en active Active
- 2016-04-07 EP EP22153298.9A patent/EP4056593A1/en active Pending
- 2016-04-07 CA CA2981954A patent/CA2981954A1/en active Pending
- 2016-04-07 ES ES16716795T patent/ES2910783T3/es active Active
- 2016-04-07 PL PL16716795T patent/PL3280734T3/pl unknown
- 2016-04-07 JP JP2017552899A patent/JP6993880B2/ja active Active
- 2016-04-07 CN CN201680032814.0A patent/CN107787330B/zh active Active
- 2016-04-07 MX MX2017012828A patent/MX2017012828A/es unknown
- 2016-04-07 EP EP16716795.6A patent/EP3280734B1/en active Active
- 2016-04-07 AU AU2016246722A patent/AU2016246722B2/en active Active
-
2020
- 2020-08-12 US US16/991,762 patent/US20210206860A1/en not_active Abandoned
-
2021
- 2021-12-10 JP JP2021200631A patent/JP7456989B2/ja active Active
-
2022
- 2022-01-25 AU AU2022200466A patent/AU2022200466B2/en active Active
-
2023
- 2023-03-23 US US18/189,065 patent/US12435146B2/en active Active
-
2024
- 2024-03-14 JP JP2024039804A patent/JP7741225B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016246722B2 (en) | 2021-10-28 |
| EP3280734A1 (en) | 2018-02-14 |
| CN107787330A (zh) | 2018-03-09 |
| CN120290577A (zh) | 2025-07-11 |
| JP7456989B2 (ja) | 2024-03-27 |
| JP2022040124A (ja) | 2022-03-10 |
| CN114539408A (zh) | 2022-05-27 |
| AU2022200466A1 (en) | 2022-02-17 |
| EP4056593A1 (en) | 2022-09-14 |
| WO2016164528A1 (en) | 2016-10-13 |
| AU2016246722A1 (en) | 2017-10-26 |
| MX2017012828A (es) | 2018-06-19 |
| US20180072806A1 (en) | 2018-03-15 |
| JP2024069463A (ja) | 2024-05-21 |
| CN107787330B (zh) | 2022-02-01 |
| JP7741225B2 (ja) | 2025-09-17 |
| CA2981954A1 (en) | 2016-10-13 |
| EP3280734B1 (en) | 2022-01-26 |
| BR112017021414A2 (pt) | 2018-07-03 |
| JP2018518153A (ja) | 2018-07-12 |
| MA41899A (fr) | 2018-02-13 |
| ES2910783T3 (es) | 2022-05-13 |
| WO2016164528A9 (en) | 2017-01-12 |
| HK1249912A1 (en) | 2018-11-16 |
| US10787515B2 (en) | 2020-09-29 |
| AU2022200466B2 (en) | 2024-06-13 |
| CN114539408B (zh) | 2025-03-11 |
| JP6993880B2 (ja) | 2022-01-14 |
| US20240076387A1 (en) | 2024-03-07 |
| US20210206860A1 (en) | 2021-07-08 |
| US12435146B2 (en) | 2025-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290160A (en) | Preparations and methods for the treatment of Duchenne muscular dystrophy and related disorders | |
| IL258211A (en) | Methods for treating muscular dystrophy | |
| DK3604544T3 (en) | Improved methods for processing dna substrates | |
| PL3660154T3 (pl) | Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a | |
| ZA201605660B (en) | Multispecific antibodies | |
| PL3227332T3 (pl) | Wielospecyficzne przeciwciała | |
| LT3221346T (lt) | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis | |
| GB201414823D0 (en) | Multispecific antibodies | |
| IL272791A (en) | Methods for treating muscular dystrophy | |
| IL252716A0 (en) | Anti-csf1r antibodies for the treatment of pvns | |
| PL3180362T3 (pl) | Przeciwciała swoiste dla MMP9 | |
| GB201522391D0 (en) | Antibody molecules | |
| IL259178A (en) | Methods for treating muscular dystrophy | |
| EP3307891B8 (en) | Combined therapy for duchenne muscular dystrophy | |
| IL249936A0 (en) | Methods for treating hypotension | |
| IL238588B (en) | Anti-flt-1 antibodies in the treatment of Duchenne muscular dystrophy | |
| SG11201704753TA (en) | Direct funds transfer process | |
| PL3280734T3 (pl) | Przeciwciała anty-flt-1 do leczenia dystrofii mięśniowej duchenne'a | |
| GB201616934D0 (en) | Process for converting nitriles | |
| IL274375A (en) | Dosing regimen of edsalonacant for the treatment of muscular dystrophy | |
| GB2526653B (en) | Sample introduction system for spectrometers | |
| PL3113919T3 (pl) | Sposób powlekania fragmentu powierzchni | |
| HK40032160A (en) | Methods for treating muscular dystrophy | |
| PL69972Y1 (pl) | Urządzenie do prowadzenia procesów biotechnologicznych | |
| TH1501003211A (th) | กระบวนการเพิ่มแรงยึดติด |